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Summary An 82-year-old male patient, who had been diagnosed with chronic heart failure
due to dilated cardiomyopathy and combined valvular disease and who had atrial ﬁbrillation
with complete atrioventricular block, was admitted to our hospital owing to the exacerbation of
chronic heart failure. During admission, the patient became aware of drowsiness during daytime
hours and had periodic apnea during sleep. Polysomnography (PSG) revealed Cheyne—Stokes
respiration with severe central sleep apnea as evidenced by an apnea—hypopnea index (AHI) of
93.5/h. Nocturnal oxygen therapy failed to sufﬁciently suppress apnea, and arousal reactions
occurred frequently. Therefore, we conducted titration by adaptive-servo ventilation (ASV;
HEART PAPTM). Consequently, subjective symptoms and respiratory sleep parameters improved.
The patient showed excellent adherence to loading the device at home. PSG at 3 months after
implementation of HEART PAPTM indicated improvement in the AHI to 13.5/h, and the patient
exhibited marked improvements in breathlessness and awareness of drowsiness during daytime
hours. HEART PAPTM was found to be a useful device for Cheyne—Stokes respiration with central
sleep apnea that is associated with chronic heart failure even for very elderly patients.
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ntroductionecent epidemiologic studies have clariﬁed that sleep-
isordered breathing (SDB) is a complication in approxi-
ately half of patients with chronic heart failure (HF), is
nvolved in the pathogenesis and exacerbation of HF, and
Published by Elsevier Ireland Ltd. All rights reserved.
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is an important clinical entity that adversely affects life
prognosis [1]. In addition, Cheyne—Stokes respiration with
central sleep apnea (CSR-CSA) that includes central apnea
and hyperventilation has been reported to be an impor-
tant prognostic factor of chronic HF [2], and closely related
to worsening quality of life (QOL) in HF patients [3]. Here
we report the case of an elderly patient with severe CSR-
CSA that was associated with chronic HF for whom one of
the interventions, adaptive-servo ventilation (ASV; HEART
PAPTM, Respironics, Inc., Murrysville, PA, USA), was markedly
effective.
Case report
An 82-year-old male patient, who suffered from New
York Heart Association class III chronic HF due to dilated
cardiomyopathy, mitral regurgitation, and tricuspid regur-
gitation and who had been implanted with a permanent
pacemaker for chronic atrial ﬁbrillation with complete atri-
oventricular block, was being treated as an outpatient. The
patient received torasemide (8mg), furosemide (20mg),
spironolactone (50mg), candesartan cilexetil (4mg), and
warfarin (3mg) and had a history of several admissions to the
hospital due to the exacerbation of HF. These medications
did not change in this hospitalization. During the present
admission due to the repeated acute exacerbation of HF,
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Figure 1 First polysomnogram. Air ﬂow and entire respiratory
decrescendo, fusiform hyperventilation’’ is repeated cyclically (2
evidenced by an apnea—hypoxemia index of 93.5 episodes/h. Among
the waveforms of Cheyne—Stokes respiration with central sleep apne13
he patient presented with periodic apnea during sleep.
e suspected that the patient’s complications included SDB
ecause he complained of drowsiness during daytime hours
nd nocturia, although his Epworth Sleepiness Score (ESS)
hich represented objective sleepiness was 4. Therefore,
e conducted polysomnography (PSG) after the improve-
ent in HF. On admission, the patient (154.7 cm in height;
4.5 kg in body weight; 92/74mmHg in blood pressure; and
0 bpm in pulse rate) showed jugular engorgement, systolic
urmurs in the apical area, and marked edema of the lower
xtremities. Blood gas analysis (under atmosphere), that
as performed prior to conducting PSG, revealed hypox-
mia and hypocapnia as evidenced by 7.47 in pH, 35.1 torr
n PCO2, 68.7 torr in PO2, and 25mEq/l in HCO3−. The
lasma brain natriuretic peptide (BNP) level was as high
s 233 pg/ml. Plain chest X-ray indicated a cardiothoracic
atio of 72%, and echocardiography exhibited a left ventric-
lar ejection fraction (LVEF) of 14%, a decrease in diffuse
ypokinesis of the left ventricular wall, severe mitral regur-
itation, and severe tricuspid regurgitation.
A polysomnogram, that was obtained after the improve-
ent in HF, is shown in Fig. 1. The patient showed severe SDB
s indicated by an apnea—hypopnea index (AHI) of 93.5/h.
mong the episodes, the central apnea index (CAI)—–mostly
howing the waveforms of CSR-CSA—–accounted for 37.9/h.
he minimum SpO2 level was 82%. Furthermore, the arousal
ndex (ArI) was 94.2/h, indicating marked sleep fragmenta-
movements are suspended (1), and so-called ‘‘crescendo-
). This chart indicates severe sleep-disordered breathing as
the episodes, the central apnea index (CAI)—–mostly showing
ea (CSR-CSA)—–accounted for 37.9 episodes/h.
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ion associated with hyperventilation. Consequently, sleep
uality was noticeably impaired. Furthermore, the patient
ad eight nocturnal micturitions, also indicating sleep frag-
entation by these episodes.
PSG indicated typical CSR-CSA. A beta-adrenergic recep-
or blocker was difﬁcult to be used for our patient because
e was hypotensive. Therefore, we considered nonphar-
acotherapy for CSR-CSA. The patient presented possible
ifﬁculty in undergoing positive pressure ventilation ther-
py because of old age and underlying disease. First, we
onducted titration by nocturnal oxygen therapy (3 L/min).
onsequently, SDB improved as indicated by an AHI of
1.4/h, with a CAI of 3.1/h. However, hypopnea considered
o be residual central and/or changing obstructive, and an
levated ArI (66.1/h) associated thereto persisted, and the
umber of nocturnal micturitions did not reduce.
Oxygen therapy failed to sufﬁciently improve respira-
ory sleep parameters and sleep quality. Therefore, we
onducted titration with HEART PAPTM (Fig. 2). Time was
equired to set initial pressures. Therefore, apnea persisted
s evidenced by an AHI of 37.6/h and a CAI of 2.6/h.
owever, the ArI reduced to 38.2/h, and slow-wave sleep
nd REM sleep—–that had not been observed during oxygen
herapy—–occurred. Furthermore, the patient had no noc-
urnal micturition and noticed, after the titration, a feeling
f sound sleep and alleviated drowsiness during daytime
ours. HEART PAPTM improved respiratory sleep parame-
w
d
2
l
b
igure 2 Polysomnogram under HEART PAPTM titration. Ventilat
nspiratory positive airway pressure (IPAP) (1), desaturation is improY. Usui et al.
ers and sleep quality and was also well-tolerated by the
atient. Therefore, the device was implemented under the
ollowing conditions: 24 cmH2O in the maximum inspira-
ory positive airway pressure (IPAP max); 10 cmH2O in the
inimum inspiratory positive airway pressure (IPAP min);
0 cmH2O in expiratory positive airway pressure (EPAP); and
5 breaths/min in respiratory rate. Subsequent follow-up on
n outpatient basis revealed excellent adherence to loading
he device. The mean duration of device use was 6.5 h/day.
dema of the lower extremities, nocturnal pollakiuria, a
eeling of sound sleep, and exertional breathlessness during
aytime hours improved.
At 3 months after implementation of HEART PAPTM, PSG
as conducted in the patient who loaded HEART PAPTM under
he same conditions as those for outpatient care. Conse-
uently, the AHI reduced to 16.3/h and the minimum SpO2
as 91%; hence, the patient showed improvement in hypox-
mia. Furthermore, the ArI also showed a marked reduction
o 13.0/h, and the improvement of both sleep depth and
EM sleep persisted from the time of implementing HEART
APTM. In addition, the patient showed no nocturnal mic-
urition during the testing. During these 3 months, there
as no change in medications for heart failure. LVEF evi-
enced by echocardiography slightly improved from 14% to
1%. However, the patient’s impression about usage is excel-
ent, and he is under continuing treatment on an outpatient
asis without readmission for 2 years.
ory volume on a breath-by-breath basis is averaged by auto
ved (2), and arousal reactions are reduced.
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Discussion
CSR-CSA is concurrently associated with approximately
30—40% of patients with chronic HF, and the following events
are considered to be involved in its pathogenesis: (1) hyper-
ventilation due to the stimulation of lung stretch receptors
induced by chronic pulmonary congestion associated with
decreased cardiac output; (2) enhanced sensitivity of cen-
tral chemoreceptors; and (3) a delay in circulation time
associated with decreased cardiac output. Namely, CSR-
CSA is considered to be the consequence of HF. However,
Lanfranchi et al. [2] have reported that the presence of
CSR-CSA itself is an independent prognostic factor for HF.
Moreover, Carmona-Bernal et al. [3] have demonstrated that
HF patients with CSR-CSA had a worse QOL than those with
HF alone. Consequently, CSR-CSA currently attracts atten-
tion as a new therapeutic target for chronic HF.
To date, oxygen therapy [4], continuous positive air-
way pressure (CPAP) [5], bi-level positive airway pressure
(BiPAP) [6], ASV [7], and other modalities have been
reported as nonpharmacologic therapies for CSR-CSA. How-
ever, an improvement in long-term prognosis has never
been reported, and no established therapeutic modality
is currently available. However, beta-adrenergic receptor
blockers and cardiac resynchronization therapy (CRT) have
been reported to reduce the CAI [8,9]. Therefore, basic
treatments for chronic HF are essential, i.e., sufﬁcient
pharmacotherapy principally consisting of beta-adrenergic
receptor blockers and CRT (in patients for whom the modal-
ity is indicated). However, our patient could not receive
these treatments for HF because of hypotension, severe tri-
cuspid regurgitation, and high age, so we had to choose
nonpharmacologic therapies for CSR-CSA.
ASV (HEART PAPTM), noninvasive positive pressure ventila-
tion (NPPV) that was developed for the purpose of treating
SDB, which is concurrently associated with chronic HF, is
principally characterized by its function of assisting IPAP
that automatically allows the sustainment of proper ven-
tilation volume in proportion to the patient’s respiratory
condition (auto IPAP). Furthermore, HEART PAPTM can set
EPAP—–that deletes the components of OSA which is present
frequently in a concurrent fashion—–and is theoretically
capable of addressing all levels of SDB in HF. We surmised
since the beginning of the present admission that NPPV was
t
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Table 1 PSG ﬁndings of before and after treatment for CSR-CSA.
Before treatment Under oxy
AHI (episodes/h) 93.5 51.4
CAI 37.9 3.1
OAI 4.9 3.1
% of TST SpO2 <90% 17.2 4.5
Lowest SpO2 (%) 81 83
ArI (episodes/h) 94.2 66.1
Sleep stage (% of TST)
1 and 2 100 97.9
SWS 0 0
REM 0 2.1
AHI: apnea—hypopnea index; CAI: central apnea index; OAI: obstructive
saturation; ArI: arousal index; SWS: slow-wave sleep; REM: rapid eye me15
ifﬁcult to be implemented for our patient because of age,
nderlying disease, and other factors. First, we conducted
octurnal oxygen therapy. Although desaturation improved,
leep quality failed to be improved due to the frequent
ccurrence of arousal reactions induced by persisting CSR-
SA. Nocturnal oxygen therapy (3 L/min) for outpatients
ith chronic HF, whose respiratory disturbance index (RDI)
n arterial blood was ≥5 episodes/h and whose LVEF was
45%, improved their QOL [4]. However, this study exam-
ned principally patients with mild chronic HF and did not
onduct nocturnal PSG in all the patients examined. There-
ore, sleep quality was not assessed. Furthermore, they
onsidered the improvement of oxygen saturation due to
xygen therapy as improvement in respiratory parameters;
herefore, they possibly underestimated respiratory events
nvolving arousal reactions. On the other hand, HEART PAPTM
ndicated increases in deep sleep and REM sleep and was
olerated by the patient rather better than oxygen ther-
py. Table 1 shows the results of PSG which was performed
efore treatment for CSR-CSA, under titration by noctur-
al oxygen therapy, titration with HEART PAPTM, and after 3
onths after implementation of HEART PAPTM. Our patient
as a very elderly with low cardiac function, for whom
PPV is generally considered difﬁcult to be implemented.
herefore, we considered that HEART PAPTM is a potentially
ffective therapeutic option also for patients for whom pos-
tive pressure therapy has been difﬁcult to be implemented
ecause of its low tolerability. Moreover, a study [5] reported
hat excessive preload reduced by CPAP might be one of
he causes for the fact that the therapy had not improved
rognosis. Our patients received extraordinary high IPAP
ressure because obstructive component did not diminish
ven 10 cmH2O of EPAP during titration. Avoiding the exces-
ive high EPAP pressure, therefore, high IPAP max pressure
as needed. During follow-up, however, our patient showed
educed edema of the lower extremities without a decrease
n blood pressure. Therefore, we regard that ASV is an effec-
ive therapy when conducted at pressures that were set by
itration under sufﬁcient observation. Kasai et al. reported
TMhat HEART PAP signiﬁcantly improved respiratory sleep
arameters and sleep parameters for chronic HF patients
ith CSR-CSA which had persisted also under the use of
PAP and BiPAP [10]. However, they studied only one night
nd did not evaluate the long-term effectiveness of HEART
gen therapy Under ASV ASV after 3 months
37.6 16.3
2.6 3.8
5.3 0
0.1 2.0
86 91
38.2 13.0
77.5 88.1
2.1 0
10.3 10.9
apnea index; TST: total sleep time; SpO2: arterial oxyhemoglobin
ovement; ASV; adaptive-servo ventilation.
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APTM for sleep quality and QOL. Unfortunately, we did not
valuate his QOL objectively. However, subjective symptoms
uch as exertional dyspnea and nocturia were dramatically
mproved. Therefore, we considered that the treatment
ith HEART PAPTM dramatically improved subjective symp-
oms and this device potentially improved patient’s QOL and
as well-tolerated even in very elderly HF patients, who did
ot receive any other treatments for CSR-CSA. We expect
hat the application criteria for ASV, method of titration,
nd other conditions be established in the future and that
large-scale clinical trial of ASV be conducted in which life
rognosis and QOL of patients with chronic HF complicated
y CSR-CSA should also be examined.
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